Dr. Nicholas Lydon CML Chronic myeloid leukemia
''Nicholas B. Lydon is a British scientist and entrepreneur. He won 2009 Lasker Clinical Award for the development of Gleevec, a selective BCR-ABL inhibitor for the treatment of chronic myeloid leukemia (CML). Lydon earned a BS in biochemistry from the University of Leeds, England and received his Ph.D in biochemistry from the University of Dundee, Scotland.''
Extract of http://en.wikipedia.org/wiki/Nicholas_Lydon
VIDEOS
2009 Lasker DeBakey Clinical Medical Research Award
March 9, 2016, Albert and Mary Lasker Foundation
Targeting the human kinome: cancer drug discovery
September 26, 2014, The Royal Society
2012 (28th) Japan Prize: Dr. Rowley / Dr. Druker / Dr. Lydon
April 24, 2012, JapanPrize
2009 Lasker DeBakey Clinical Medical Research Award
March 9, 2016, Albert and Mary Lasker Foundation
2009 Lasker DeBakey Clinical Medical Research Award
March 9, 2016, Albert and Mary Lasker Foundation
Targeting the human kinome: cancer drug discovery
September 26, 2014, The Royal Society
2012 (28th) Japan Prize: Dr. Rowley / Dr. Druker / Dr. Lydon
April 24, 2012, JapanPrize
2009 Lasker DeBakey Clinical Medical Research Award
March 9, 2016, Albert and Mary Lasker Foundation